Coward R A
Department of Renal Medicine, Royal Preston Hospital, UK.
Postgrad Med J. 1989 May;65(763):302-6. doi: 10.1136/pgmj.65.763.302.
The complications and costs of chronic dialysis in 4 patients with renal failure due to multiple myeloma are presented. In three patients the paraprotein responded to chemotherapy though without recovery of renal function. These three patients are alive after 18, 16 and 15 months of dialysis, the other dying after 7 months. Hospital admissions ranged from 26 to 74 days per year with infections accounting for 54 to 87% of admission days, 62.5% of which occurred during the first three months of dialysis treatment, with an incidence of 2.4 to 6.9 admissions episodes per year. An in-house audit of our chronic dialysis patients indicated that treatment of myeloma patients is 5-33% more expensive. The extra cost in such high risk patients is mostly due to the greater number and longer duration of hospital admissions for infection. The other extra costs (in decreasing value) of blood products, antibiotics and chemotherapy are relatively small in comparison to in-patient treatment.
本文介绍了4例因多发性骨髓瘤导致肾衰竭患者的慢性透析并发症及费用情况。3例患者的副蛋白对化疗有反应,但肾功能未恢复。这3例患者在透析18、16和15个月后仍存活,另1例在7个月后死亡。每年住院天数为26至74天,感染占住院天数的54%至87%,其中62.5%发生在透析治疗的前三个月,每年入院次数为2.4至6.9次。对我们慢性透析患者的内部审计表明,骨髓瘤患者的治疗费用高出5%至33%。这类高危患者的额外费用主要是由于因感染住院的次数更多、时间更长。与住院治疗相比,血液制品、抗生素和化疗的其他额外费用(按价值递减)相对较小。